• PN: B111449


45x Ab-conjugated beads (S5P9 - human TGFα Ab-bead). PN: B111449A. One vial containing 100 µL of anti-human TGFα conjugated to AimPlex Bead S5P9.

25x Biotin-detection Ab (human TGFα Biotin-dAb). PN: B111449B. One vial containing 100 µL of biotinylated anti-human TGFα.

Lyophilized Standard Mix-Human Group 4 Panel B, 10-Plex. PN: HG40010. One vial containing lyophilized recombinant human GASP-1, IFNβ, ANGPT-1, Insulin, Leptin, MIF, Resistin, Survivin, TGFα, and TPO. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human TGFα.  Can be multiplexed with other analytes in Human Group 4.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 4: Negligible

Sample volume: 15 µL/test


Survivin, also called Baculoviral Inhibitor of apoptosis Repeat-Containing 5 (BIRC5), is a member of the inhibitor of apoptosis (IAP) family. Survivin functions to inhibit caspase activation which leads to the negative regulation of apoptosis. The survivin is expressed highly in most human tumours and fetal tissue, but is completely absent in terminally differentiated cells suggesting that survivin might provide a new target for cancer therapy that would discriminate between transformed and normal cells. Survivin expression is also highly regulated by the cell cycle and is only expressed in the G2-M phase. It is known that survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. The molecular mechanisms of survivin regulation are still not well understood, but regulation of survivin seems to be linked to the p53 protein. Diseases associated with BIRC5 include serous cystadenocarcinoma and ovarian serous cystadenocarcinoma.


1.      Ojeda, S.; Ma, Y.; Rage, F. The transforming growth factor alpha gene family is involved in the neuroendocrine control of mammalian puberty. Mol. Psychiatry 1997, 2, 355.

2.      Ferrer, I.; Alcantara, S.; Ballabriga, J.; Olive, M.; Blanco, R.; Rivera, R.; Carmona, M.; Berruezo, M.; Pitarch, S.; Planas, A. Transforming growth factor- α (TGF-α) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog. Neurobiol. 1996, 49, 99.

3.      Coffey, R.; Gangarosa, L.; Damstrup, L.; Dempsey, P. Basic actions of transforming growth factor- α and related peptides. Eur. J. Gastroen. Hepat. 1995, 7, 923.

4.      McInnes, C; Wang, J; Al Moustafa, AE; Yansouni, C; O'Connor-McCourt, M; Sykes, BD (1998). "Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand. Design, solution structure, and activity of TGF-alpha 8-50".". J. Biol. Chem 273 (42): 27357–63. doi:10.1074/jbc.273.42.27357.